Dr Abin Thomas

(he/him)

2025

• Aleem, A. et al., 2025. Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice. Clinical Lymphoma, Myeloma and Leukemia 25 (1), pp.50-56. (10.1016/j.clml.2024.08.006)
• Knapper, S. et al. 2025. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood (10.1182/blood.2025031006)
• Potter, N. et al., 2025. Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. The Lancet Haematology 12 (5), pp.e346-e356. (10.1016/S2352-3026(25)00037-7)
• Russell, N. H. et al., 2025. Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML. Blood Advances 9 (24), pp.6455-6466. (10.1182/bloodadvances.2025017244)
• Russell, N. H. , Thomas, A. and Freeman, S. D. 2025. Reply to: Treatment intensification based on residual disease in elderly patients with AML. Journal of Clinical Oncology (10.1200/JCO-25-00198)
• Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)
• Van Der Maas, N. G. et al., 2025. A revised prognostic model for patients with acute myeloid leukemia and first relapse. Blood Advances 9 (15), pp.3853-3864. (10.1182/bloodadvances.2025015797)

2024

• Versluis, J. et al., 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42 (34), pp.4084-4094. (10.1200/JCO.23.02631)

2023

• Freeman, S. D. et al., 2023. Fractionated versus single dose Gemtuzumab Ozogamicin with determinants of benefit in older AML: UK NCRI AML18 Trial. Blood 142 (20), pp.1697-1707. (10.1182/blood.2023020630)

2022

• Russell, N. H. et al., 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107 (7), pp.1518-1527. (10.3324/haematol.2021.279010)

2021

• AlAmmari, M. et al., 2021. The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population.. PLoS ONE 16 (5) e0250502. (10.1371/journal.pone.0250502)
• Ammari, M. A. et al., 2021. Mental health outcomes amongst health care workers during COVID 19 pandemic in Saudi Arabia. Frontiers in Psychiatry 11 619540. (10.3389/fpsyt.2020.619540)
• Esba, L. C. A. et al., 2021. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort sudy. Infectious Diseases and Therapy 10 , pp.253-268. (10.1007/s40121-020-00363-w)
• Nagraj, S. et al., 2021. Role of invasive mechanical ventilation and ECMO in the management of COVID-19: a systematic review. Indian Journal of Critical Care Medicine 25 (6), pp.691-698. (10.5005/jp-journals-10071-23870)
• Tiong, I. S. et al., 2021. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances 5 (23), pp.5107-5111. (10.1182/bloodadvances.2021005455)
• Yousef, C. C. et al., 2021. Liraglutide effects on glycemic control and weight in patients with Type 2 Diabetes mellitus: a real-world, observational study and brief narrative review. Diabetes Research and Clinical Practice 177 108871. (10.1016/j.diabres.2021.108871)

2020

• Tiong, I. S. et al., 2020. The natural history of NPM1MUT Measurable Residual Disease (MRD) positivity after completion of chemotherapy in Acute Myeloid Leukemia (AML). Presented at: 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020) Virtual 5-8 December 2020. Vol. 136.Vol. Supple. American Society of Hematology. , pp.25-27. (10.1182/blood-2020-140296)
• Yousef, C. C. et al., 2020. Adoption of a personal health record in the digital age: Cross-sectional study. Journal of Medical Internet Research 22 (10) e22913. (10.2196/22913)

2019

• Alaskar, A. et al., 2019. Chemotherapy effect on fertility in male patients with Hodgkin and Non-Hodgkin Lymphoma. Presented at: 61st American Society of Hematology Annual Meeting & Exposition (ASH 2019) Orlando, FL, USA 07-10 December 2019. Vol. 134.Vol. Supple. American Society of Hematology. , pp.5865. (10.1182/blood-2019-126447)
• Alotaibi, B. et al., 2019. Tuberculosis knowledge, attitude and practice among healthcare workers during the 2016 Hajj. PLoS ONE 14 (1) e0210913. (10.1371/journal.pone.0210913)
• Shaheeen, N. A. et al., 2019. Reducing defects in the datasets of clinical research studies: conformance with data quality metrics. BMC Medical Research Methodology 19 98. (10.1186/s12874-019-0735-7)
• Shaheen, N. A. et al., 2019. Paternal postnatal depression among fathers of newborn in Saudi Arabia. American Journal of Men's Health 13 (1), pp.1-12. (10.1177/1557988319831219)